• Earlier this week, the American Academy of Orthopaedic Surgeons launched an online Pain Management Resource Center to support clinicians and patients across the full orthopaedic care pathway, developed with founding partners Curonix, Pacira BioSciences, Vertex Pharmaceuticals and Viatris.
• Viatris’ role as a founding partner in this comprehensive pain education initiative underscores its focus on supporting musculoskeletal pain care beyond its product portfolio.
• We’ll now examine how Viatris’ founding role in AAOS’s Pain Management Resource Center may influence its existing investment narrative.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Viatris Investment Narrative Recap

To own Viatris, you need to believe its broad generics base and emerging pipeline in pain and chronic disease can gradually improve profitability despite pricing and regulatory pressures. The AAOS Pain Management Resource Center partnership is directionally consistent with Viatris’ push into higher value pain care, but it does not materially change the near term focus on execution around new product launches and ongoing operational and regulatory risks.

Among recent announcements, the FDA’s acceptance of Viatris’ NDA for fast acting meloxicam stands out as most relevant. If approved, this non opioid pain therapy could become a more meaningful commercial catalyst than the AAOS education initiative itself, potentially complementing Viatris’ role in orthopaedic pain management and supporting the broader effort to shift its mix toward complex, higher margin products.

Yet despite these positives, investors should still pay close attention to the risk that ongoing pricing reform and regulatory scrutiny could...

Viatris' narrative projects $15.4 billion revenue and $954.5 million earnings by 2029. This requires 1.8% yearly revenue growth and a $1.25 billion earnings increase from -$296.5 million today.

Uncover how Viatris' forecasts yield a $17.50 fair value, in line with its current price.

Exploring Other Perspectives

While the consensus view focuses on steady incremental progress, the most optimistic analysts see a larger upside, with revenue reaching about US$15.6 billion and earnings around US$1.9 billion by 2029, so this new pain focused collaboration could eventually nudge expectations further in either direction.

Explore 7 other fair value estimates on Viatris - why the stock might be worth 39% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Viatris research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Viatris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viatris' overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.